Meeting Type:         Regular Meeting
Meeting Date:          June 12, 2018
Meeting Location:    Legislative Office Building, Room 1D
Meeting Agenda:      June 12, 2018
Meeting Materials:   2018 Legislative Update - Final
Meeting Minutes:     June 12, 2018 Minutes - DRAFT
Meeting Votes:         June 12, 2018 Votes

 

Meeting Type:          Regular Meeting - CANCELLED
Meeting Date:          May 8, 2018
 

 

Meeting Type:          Regular Meeting
Meeting Date:          Tuesday, April 10, 2018
Meeting Location:    Legislative Office Building, Room 1C
Meeting Time:          9:00 A.M.-11:00 A.M.
Meeting Agenda:      April 10, 2018 Agenda
Meeting Minutes:     April 10, 2018 Minutes  DRAFT
Meeting Materials:  
CMIR & Facility Fee Presentation

                                 HCC HIT Update

 

Meeting Type:          Regular Meeting (Cancelled due to weather)
Meeting Date:          Tuesday, March 13, 2018
Meeting Location:    State Capitol Room 310
Meeting Time:          9:00 A.M.-12:00 P.M.
Meeting Agenda:      3/13/2018 Agenda
Meeting Minutes:     Meeting cancelled due to weather
Meeting Materials: 

 

Meeting Type:           Regular Meeting
Meeting Date:           Tuesday, February 13, 2018
Meeting Location:     State Capitol Room 310
Meeting Time:           9:00 A.M.- 12:00 P.M.
Meeting Agenda:       2/13/2018 Agenda
Meeting Minutes:      2/13/2018 Draft

Meeting Materials:    Boehringer Ingelheim Comments
                                  Recommendations on Pharmaceutical Cost Containment Strategies - Final Report

 

Meeting Type:        Regular Meeting
Meeting Date:        Tuesday, January 16, 2018
Meeting Location: State Capitol Room 310
Meeting Time:        9:00 A.M. -12:00 P.M.
Meeting Agenda:     1/16/2018

Meeting Minutes:    1/16/2018
Meeting Materials: 

Public Comment on Draft Recommendations on Pharmaceutical Costs

 

Over the last year the Cabinet has engaged a variety of stakeholders including industry experts, government leaders, researchers, consumers, providers, health plans and advocates, to help the identify a set of detailed recommendations to address pharmaceutical costs. The draft report of recommendations represents the combined efforts of various workgroups and Cabinet discussion. After initial review and consideration of the recommendations of each workgroup, the Cabinet directed the workgroup chairs to collaborate to prioritize the recommendations and combine them into one report to present to the public for comment.  Recommendations are organized into two categories; those that require legislation and those that can be implemented using existing administrative authority. 

 

After public feedback has been collected, the Cabinet will again consider the recommendations at its January 16, 2018 meeting and may change and reprioritize the list prior to sending a final report to the Governor and the legislature for consideration.

 

Written public comment will be accepted until February 6, 2018 at 4:30 p.m. Comments should be sent to Victoria Veltri, Chief Health Policy Advisor, at victoria.veltri@ct.gov.  

 All comments will be posted on the Cabinet website with the January 16th meeting materials.

 

Public Comment on Draft Report

 

Draft Report:  Recommendations on Pharmaceutical Costs

 

Consolidated Public Comments

 

Individual Public Comments

Association for Accessible Medicine

Biotechnology Innovation Organization

Burton and Patricia Conway

CT Association of Health Plans

CT Legal Aid

CT State Innovation Model   

CT State Innovation Model Consumer Advisory Board 

CT State Medical Society

Diane Belford - High Cost of USA Prescription Drugs

Epilepsy Foundation 

Joshua Agelis  

Kathy Flaherty

Lesley Bennett

Linda Bronstein  

National Association of Social Workers 

Patients for Affordable Drugs

Pfizer

Pharmaceutical Care Management Association

PhRMA Comments

Planned Parenthood

Public Citizen

Ross Kristal

Sanofi

Stephen Smith

Supriyo Chatterjee

Susan Israel

Universal Health Care Foundation

Velandy Manohar

William McKinney

Yale School of Management Cabinet Rx